Risiken diabetesassoziierter Komorbiditäten in Subgruppen des Typ-2-Diabetes

Zusammenfassung

Diabetes mellitus ist eine vielfältige Erkrankung, die sich in ihren klinischen Merkmalen sowie im Risiko für begleitende Krankheiten und Komplikationen unterscheidet. Bisherige Klassifikationen haben sich hauptsächlich auf die Unterscheidung zwischen Typ-1- und Typ-2-Diabetes konzentriert, abgesehen von Gestationsdiabetes und anderen spezifischen Formen mit bekannter Ursache. Durch die Nutzung einfacher Variablen ist es nun möglich, die verschiedenen Typen von Diabetes in Subgruppen/Cluster einzuteilen. Diese Einteilung ermöglicht eine genauere Bewertung spezifischer Patientengruppen und könnte in Zukunft personalisierte Ansätze für Prävention, Diagnose und Therapie ermöglichen.

Abstract

Diabetes mellitus is a diverse disease that differs in its clinical features as well as the risk of concomitant diseases and complications. Previous classifications have focused primarily on distinguishing between type 1 and type 2 diabetes, apart from gestational diabetes and other specific forms with a known cause. By using simple variables, it is now possible to divide the different types of diabetes into subgroups/clusters. This classification enables a more precise assessment of specific patient groups and could enable personalized approaches for prevention, diagnosis and therapy in the future.

Was ist wichtig?

• Im Bestreben nach einer verbesserten Versorgung von Diabetespatienten eröffnen aktuelle Cluster-Analysen mit ihren resultierenden Subgruppen neue bedeutende Forschungsmöglichkeiten.

• Personen mit Diabetes zeigen eine breite Palette von Stoffwechselmerkmalen, die es ermöglichen, Cluster anhand primärer ätiologischer Parameter wie Autoimmunität, Alter, Body-Mass-Index, Betazellfunktion und Insulinsensitivität zu klassifizieren.

• Diese Parameter befähigen eine differenzierte Einteilung, die im Zusammenhang mit dem Auftreten von diabetesbedingten Komplikationen steht.

Schlüsselwörter

Insulinresistenz - diabetische Nierenerkrankungen - kardiovaskuläres Risiko

Keywords

insulin resistance - diabetic kidney diseases - cardiovascular risk

Publication History

Article published online:
31 July 2024

• Literatur

• 1 Petersmann A, Müller-Wieland D, Müller UA. et al. Definition, Classification and Diagnosis of Diabetes Mellitus. Exp Clin Endocrinol Diabetes 2019; 127: S1-S7 DOI: 10.1055/a-1018-9078. (PMID: 31860923)
• 2 Ahlqvist E, Storm P, Karajamaki A. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018; 6: 361-369 DOI: 10.1016/s2213-8587(18)30051-2.
• 3 Udler MS, Kim J, von Grotthuss M. et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis. PLoS Med 2018; 15: e1002654 DOI: 10.1371/journal.pmed.1002654.
• 4 Zaharia OP, Strassburger K, Strom A. et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 2019; 7: 684-694 DOI: 10.1016/s2213-8587(19)30187-1.
• 5 Wagner R, Heni M, Tabák AG. et al. Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med 2021; 27: 49-57 DOI: 10.1038/s41591-020-1116-9. (PMID: 33398163)
• 6 Herder C, Roden M. A novel diabetes typology: towards precision diabetology from pathogenesis to treatment. Diabetologia 2022; 65: 1770-1781 DOI: 10.1007/s00125-021-05625-x. (PMID: 34981134)
• 7 Zaharia OP, Herder C, Roden M. Präzisionsmedizin in der Diabetologie. Diabetologie 2023; 19: 106-111 DOI: 10.1007/s11428-023-01006-7.
• 8 Szendroedi J, Saxena A, Weber KS. et al. Cohort profile: the German Diabetes Study (GDS). Cardiovasc Diabetol 2016; 15: 59 DOI: 10.1186/s12933-016-0374-9. (PMID: 27053136)
• 9 Zaharia OP, Szendrödi J. Subphänotypen des Diabetes. Diabetologe 2019; 15: 288-295 DOI: 10.1007/s11428-019-0451-2.
• 10 Zaharia OP, Bobrov P, Strassburger K. et al. Metabolic Characteristics of Recently Diagnosed Adult-Onset Autoimmune Diabetes Mellitus. J Clin Endocrinol Metab 2018; 103: 429-437 DOI: 10.1210/jc.2017-01706. (PMID: 29220505)
• 11 Simon MC, Moller-Horigome A, Strassburger K. et al. Correlates of Insulin-Stimulated Glucose Disposal in Recent-Onset Type 1 and Type 2 Diabetes. J Clin Endocrinol Metab 2019; 104: 2295-2304 DOI: 10.1210/jc.2018-02057. (PMID: 30689904)
• 12 Kupriyanova Y, Zaharia OP, Bobrov P. et al. Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus. J Hepatol 2021; 74: 1028-1037 DOI: 10.1016/j.jhep.2020.11.030. (PMID: 33259845)
• 13 Zou X, Zhou X, Zhu Z. et al. Novel subgroups of patients with adult-onset diabetes in Chinese and US populations. Lancet Diabetes Endocrinol 2019; 7: 9-11 DOI: 10.1016/S2213-8587(18)30316-4.
• 14 Schön M, Prystupa K, Mori T. et al. Analysis of type 2 diabetes heterogeneity with a tree-like representation: insights from the prospective German Diabetes Study and the LURIC cohort. Lancet Diabetes Endocrinol 2024; 12: 119-131 DOI: 10.1016/s2213-8587(23)00329-7.
• 15 Matthews DR, Hosker JP, Rudenski AS. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419 DOI: 10.1007/bf00280883.
• 16 Bönhof GJ, Herder C, Strom A. et al. Emerging biomarkers, tools, and treatments for diabetic polyneuropathy. Endocr Rev 2019; 40: 153-192 DOI: 10.1210/er.2018-00107. (PMID: 30256929)
• 17 Gancheva S, Jelenik T, Alvarez-Hernandez E. et al. Interorgan Metabolic Crosstalk in Human Insulin Resistance. Physiol Rev 2018; 98: 1371-1415 DOI: 10.1152/physrev.00015.2017. (PMID: 29767564)
• 18 Stefan N, Roden M. Diabetes und Fettleber. Diabetologe 2020; 16: 36-39 DOI: 10.1007/s11428-019-00567-w.
• 19 Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature 2019; 576: 51-60 DOI: 10.1038/s41586-019-1797-8. (PMID: 31802013)
• 20 Targher G, Corey KE, Byrne CD. et al. The complex link between NAFLD and type 2 diabetes mellitus – mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021; 18: 599-612 DOI: 10.1038/s41575-021-00448-y.
• 21 Pilz S, Scharnagl H, Tiran B. et al. Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease. J Clin Endocrinol Metab 2006; 91: 2542-2547 DOI: 10.1210/jc.2006-0195.
• 22 Tanabe H, Masuzaki H, Shimabukuro M. Novel strategies for glycaemic control and preventing diabetic complications applying the clustering-based classification of adult-onset diabetes mellitus: A perspective. Diabetes Res Clin Pract 2021; 180: 109067 DOI: 10.1016/j.diabres.2021.109067. (PMID: 34563587)
• 23 Herder C, Maalmi H, Strassburger K. et al. Differences in Biomarkers of Inflammation Between Novel Subgroups of Recent-Onset Diabetes. Diabetes 2021; 70: 1198-1208 DOI: 10.2337/db20-1054.
• 24 Ratter-Rieck JM, Maalmi H, Trenkamp S. et al. Leukocyte Counts and T-Cell Frequencies Differ Between Novel Subgroups of Diabetes and Are Associated With Metabolic Parameters and Biomarkers of Inflammation. Diabetes 2021; 70: 2652-2662
• 25 Saatmann N, Zaharia OP, Strassburger K. et al. Physical fitness and cardiovascular risk factors in the novel diabetes subgroups. J Clin Endocrinol Metabo 2022; 107: 1127-1137 DOI: 10.1210/clinem/dgab810. (PMID: 34748634)
• 26 Haug N, Deischinger C, Gyimesi M. et al. High-risk multimorbidity patterns on the road to cardiovascular mortality. BMC Med 2020; 18: 44 DOI: 10.1186/s12916-020-1508-1. (PMID: 32151252)
• 27 Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol 2018; 14: 99-114 DOI: 10.1038/nrendo.2017.173. (PMID: 29286050)
• 28 Dwibedi C, Ekström O, Brandt J. et al. Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nat Metab 2024; 6: 50-60 DOI: 10.1038/s42255-023-00943-3.
• 29 Mingrone G, Panunzi S, De Gaetano A. et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2021; 397: 293-304 DOI: 10.1016/S0140-6736(20)32649-0.
• 30 Raverdy V, Cohen RV, Caiazzo R. et al. Data-driven subgroups of type 2 diabetes, metabolic response, and renal risk profile after bariatric surgery: a retrospective cohort study. Lancet Diabetes Endocrinol 2022; 10: 167-176 DOI: 10.1016/S2213-8587(22)00005-5. (PMID: 35148818)
• 31 Del Prato S. Heterogeneity of diabetes: heralding the era of precision medicine. Lancet Diabetes Endocrinol 2019; 7: 659-661 DOI: 10.1016/S2213-8587(19)30218-9. (PMID: 31345775)
• 32 Udler MS, Kim J, von Grotthuss M. et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis. PLoS Med 2018; 15: e1002654 DOI: 10.1371/journal.pmed.1002654.
• 33 Bönner F, Jung C, Polzin A. et al. SYSTEMI – systemic organ communication in STEMI: design and rationale of a cohort study of patients with ST-segment elevation myocardial infarction. BMC Cardiovasc Disord 2023; 23: 232 DOI: 10.1186/s12872-023-03210-1.